

# SEQUENCE LISTING

<110> Numab Innovation AG

<120> NOVEL ANTI-HSA ANTIBODIES

<130> 114034P877PC

<150> US62/515,293

<151> 2017-06-05

<150> EP17195783,0

<151> 2017-10-10

<160> 10

<170> PatentIn version 3.5

<210> 1

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> recombinant antibody sequence

<400> 1

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Ile | Gln | Met | Thr | Gln | Ser | Pro | Ser | Ser | Leu | Ser | Ala | Ser | Val | Gly |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asp | Arg | Val | Thr | Ile | Thr | Cys | Gln | Ser | Ser | Glu | Ser | Val | Tyr | Ser | Asn |
|     |     | 20  |     |     |     |     | 25  |     |     |     |     |     | 30  |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Gln | Leu | Ser | Trp | Tyr | Gln | Gln | Lys | Pro | Gly | Gln | Pro | Pro | Lys | Leu |
|     |     | 35  |     |     |     |     | 40  |     |     |     |     | 45  |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Ile | Tyr | Asp | Ala | Ser | Asp | Leu | Ala | Ser | Gly | Val | Pro | Ser | Arg | Phe |
|     | 50  |     |     |     |     | 55  |     |     |     |     | 60  |     |     |     |     |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ser | Gly | Ser | Gly | Ser | Gly | Thr | Asp | Phe | Thr | Leu | Thr | Ile | Ser | Ser | Leu |
| 65  |     |     |     |     | 70  |     |     |     |     | 75  |     |     |     |     | 80  |

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Pro | Glu | Asp | Phe | Ala | Thr | Tyr | Tyr | Cys | Ala | Gly | Gly | Phe | Ser | Ser |
|     |     |     |     | 85  |     |     |     |     | 90  |     |     |     |     | 95  |     |

Ser Ser Asp Thr Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly  
100 105 110

<210> 2  
<211> 121  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> recombinant antibody sequence

<400> 2

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Leu Ser Ser Asn  
20 25 30

Ala Met Gly Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Tyr Ile  
35 40 45

Gly Ile Ile Ser Val Gly Gly Phe Thr Tyr Tyr Ala Ser Trp Ala Lys  
50 55 60

Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr Leu  
65 70 75 80

Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Thr Tyr Phe Cys Ala  
85 90 95

Arg Asp Arg His Gly Gly Asp Ser Ser Gly Ala Phe Tyr Leu Trp Gly  
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser  
115 120

<210> 3  
<211> 110

<212> PRT  
<213> Artificial Sequence

<220>  
<223> recombinant antibody sequence

<400> 3

Asp Val Val Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly  
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ile Ile Ser Ser Arg  
20 25 30

Ser Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile  
35 40 45

Tyr Gln Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly  
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro  
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Cys Thr Tyr Ile Asp Ser Asn  
85 90 95

Phe Gly Ala Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly  
100 105 110

<210> 4  
<211> 121  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> recombinant antibody sequence

<400> 4

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly  
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Ser  
20 25 30

Tyr Trp Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp  
35 40 45

Val Gly Cys Val Phe Thr Gly Asp Gly Thr Thr Tyr Tyr Ala Ser Trp  
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val  
65 70 75 80

Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Thr Tyr Phe  
85 90 95

Cys Ala Arg Pro Val Ser Val Tyr Tyr Tyr Gly Met Asp Leu Trp Gly  
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser  
115 120

<210> 5  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> recombinant antibody sequence

<400> 5

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly  
1 5 10 15

Gly Gly Gly Ser  
20

<210> 6  
<211> 11  
<212> PRT  
<213> Artificial Sequence

<220>

<223> recombinant antibody sequence

<400> 6

Phe Gly Thr Gly Thr Lys Val Thr Val Leu Gly  
1 5 10

<210> 7

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> recombinant antibody sequence

<400> 7

Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly  
1 5 10

<210> 8

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> recombinant antibody sequence

<400> 8

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser  
1 5 10

<210> 9

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> recombinant antibody sequence

<400> 9

Gly Gly Gly Gly Ser  
1 5

<210> 10  
<211> 15  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> recombinant antibody sequence

<400> 10

|     |     |     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Gly | Gly | Gly | Ser | Gly | Gly | Gly | Gly | Ser | Gly | Gly | Gly | Gly | Ser |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |     | 15  |